Sign In

Ryan Fukushima

Chief Operating Officer at Tempus | CEO at Pathos

Ryan Fukushima has played a pivotal role in developing Tempus with a focus on innovation, collaboration, and data-driven insights in the realm of precision medicine in healthcare.

Under Ryan's leadership, Tempus has amassed a substantial multimodal dataset in oncology, partnering with medical professionals and researchers to enhance treatment outcomes.

With a wealth of over 100PB of data, Tempus is at the forefront of leveraging AI to derive crucial insights that advance patient care and drive the field of precision medicine forward.

Ryan Fukushima's contributions have garnered recognition, including a placement in Endpoints News' prestigious list of top 20 leaders under 40 in biopharma and biotech in 2023.

Ryan has a solid educational background with an MBA in Business from the University of Michigan and a Bachelor of Science in Engineering from California Polytechnic State University-San Luis Obispo.

His professional experience includes leadership roles at Pathos, Tempus, Inc., Lightbank, and Hyde Park Venture Partners, where he honed his skills and expertise in the realms of entrepreneurship, operations, and venture capital.

Highlights

Apr 9 · linkedin

Using multimodal data to refine patient selection strategies is a crucial step in precision oncology therapeutic development.

📖 CBP/P300 have been associated with several transcription factors in cancer, but there's a need to look beyond somatic mutations in those genes.

🔬 Bonnie Dougherty's oral presentation at American Association for Cancer Research showcased how novel AI approaches can identify patient selection strategies to stratify metastatic castrate-resistant prostate cancer into a set of biomarker-defined subgroups.

It's inspiring to work with brilliant scientists and researchers at Pathos who are fueling AI approaches with multimodal data to uncover new development paths for promising therapeutics like Pocenbrodib.

#PrecisionMedicine #PrecisionOncology #AIinOncology #AACR24

Nov 28 · linkedin

On 12/6, I'm excited for a live discussion with Gilead Sciences's Scott Patterson (Ph.D.), Vice President of Biomarker Sciences, and Shahed Iqbal, PhD, Senior Director and Head of Molecular Epidemiology, Biomarker Sciences. Come join us to hear how Gilead uses #RWD to achieve early successes in translational biomarker research and discovery. Sign up link: https://tempus.co/3h71Ksl

#multimodal #data #precisionmedicine #data4good

Ryan Fukushima
Add to my network

Location

Greater Chicago Area